NVMDF - NVMDF STOCK NEWS

Novamind Inc. (CSE:NM)(OTC PINK:NVMDF) has launched a new Client Care Center in Murray, Utah, to manage the rising demand for its psychedelic treatment services. This expansion comes ahead of schedule, with an expected increase in client visits from 20,000 in 2020 to 65,000 in 2021, marking a 225% growth. The company aims to enhance client support by responding to approximately 700 calls daily and coordinating complex care needs. Novamind plans to expand its clinic network to eight by September 2021, ensuring high service quality as it scales its operations.

Novamind Inc. (OTC PINK:NVMDF) will present at the SNN Planet MicroCap Showcase on April 22, 2021, at 10:00 AM EST, led by CEO Yaron Conforti. The presentation will discuss the company's vision for expanding access to psychedelic medicine, including their clinical and research milestones and future plans. Additionally, Novamind will participate in a panel titled 'Past, Present and Future of Psychedelics' on April 20, 2021, at 7:00 PM EST. Novamind operates a network of clinics focusing on ketamine-assisted psychotherapy and clinical research for psychedelic treatments.

Novamind Inc. will present at the SNN Planet MicroCap Showcase on April 22, 2021, at 10:00 AM EST. CEO Yaron Conforti will discuss the company's vision for expanding access to psychedelic medicine, including its recent milestones and clinical infrastructure. Additionally, Novamind will participate in a panel titled "Past, Present and Future of Psychedelics" on April 20, 2021, at 7:00 PM EST. Investors can tune in to the events via the provided links for webcast and one-on-one meetings.

Novamind (CSE:NM)(OTC PINK:NVMDF) will participate in the Benzinga Biotech Small Cap Conference on March 25, 2021. The company’s CEO, Yaron Conforti, will present its vision for scaling access to psychedelic medicine at 9:25 AM EST. Conforti highlighted Novamind's growth since 2016 and the recent agreement to serve as a key clinical trial site for Merck. Additionally, Dr. Reid Robison, Novamind's Chief Medical Officer, will join a panel discussion on psychedelic therapies at 1:10 PM EST.

Novamind Inc. has announced that its subsidiary, Cedar Clinical Research, will serve as a key site for a clinical trial focused on treatment-resistant depression, in partnership with Merck & Co.. The phase II study aims to evaluate the efficacy and safety of Merck's new drug, MK-1942. Starting in March 2021, this trial highlights CCR's expertise in conducting clinical trials in neuropsychiatry. With seven ongoing trials, CCR's collaboration with Merck underscores its position in the growing market of mental health therapeutics.

Novamind Inc. (OTC PINK:NVMDF) has appointed Joseph Braganza as Senior Vice President, Head of M&A, effective March 3, 2021. Braganza, who has 20 years of experience in mergers and acquisitions, previously led M&A at Canadian Addiction Treatment Centres and held senior roles at People Corp. and Rexall Health Solutions. His role will focus on accelerating Novamind's expansion through strategic acquisitions in the psychedelic medicine sector. CEO Yaron Conforti expressed confidence in Braganza's ability to drive growth and integrate new businesses.

Novamind Inc. (CSE:NM, OTC PINK:NVMDF) reported $1.29 million in fiscal Q2 2021 revenue, a 47% increase from the previous quarter. The company has successfully expanded its clinic capacity and facilitated over 20,000 client visits in 2020, reflecting a surge in demand for mental health services. Despite a net loss of $3.57 million due to expansion and listing expenses, Novamind maintains a strong cash position of $10.87 million and continues to grow its network of clinics and treatments.

Novamind Inc. (CSE:NM) (OTC PINK:NVMDF) will participate in the Benzinga Cannabis Capital Conference on February 25-26, 2021. CEO Yaron Conforti will present Novamind's mission to enhance access to psychedelic medicine on February 26 at 1:30 PM EST. Following this, Chief Medical Officer Dr. Reid Robison will join a panel discussion on psychedelics at 1:50 PM EST. The Company specializes in mental health services utilizing psychedelic treatments and operates clinics and research sites to advance clinical studies.

Novamind has been included in the North American Psychedelics Index as a fast entry addition, underscoring its position in the psychedelic medicine industry. This milestone comes less than two months after the company's public debut on January 5, 2021. The inclusion allows Novamind to gain exposure to a broader investor base through the Horizons Psychedelic Stock Index ETF. The ETF aims to track the performance of North American life sciences companies engaged in the psychedelics market. CEO Yaron Conforti highlighted that this recognition aligns with Novamind's leadership in mental healthcare.